msc + gm-csf

MSC + GM-CSF is a combination therapy involving mesenchymal stem cells (MSCs) and granulocyte–macrophage colony-stimulating factor (GM-CSF). MSCs are multipotent stromal cells capable of differentiating into various cell types, including bone, cartilage, and fat, and have immunomodulatory and regenerative properties[4]. GM-CSF is a cytokine that stimulates the mobilization of stem cells like MSCs from the bone marrow into the peripheral blood by inducing a hypoxic and proteolytic microenvironment in the bone marrow and upregulating CXCR4 expression, which is crucial for migration via the SDF-1–CXCR4 axis[1]. This combination has been explored in preclinical settings, where GM-CSF administration (e.g., 50 μg/kg subcutaneously for 5 days in rats) leads to a significant increase in circulating MSCs, while reducing the number of MSCs in the bone marrow, suggesting active mobilization[1]. The mechanism involves modulation of the bone marrow niche and enhancement of MSC migration, potentially making this combination useful for regenerative or immunomodulatory therapies. There is no information available in the provided data about a commercially available, specific combination product named "MSC + GM-CSF," nor about large-scale clinical trials, approvals, or a specific developer/manufacturer for this particular combination.